LegoChem Biosciences Inc. or LCB operates in the development of new pharmaceuticals based on medicinal chemistry through joint and contract research. The Company is engaged in the development of new drugs for therapy such as antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, antibody-drug-conjugates (ADC), among others. LCB uses platform technology called "LegoChemistry" and operates using new drug development system called Gate Decision System. LegoChem Biosciences was established in May, 2006 with a joint contract with KIST (Anticancer DDR-2) and Yonsei University.
Headquarters
8-26 Munpyeongseo-Ro, Daedeok-Gu, Gwangyeok-Si
Daejeon; Daejeon;
Contact Details: Purchase the Legochem Biosciences Inc. report to view the information.
Website: http://www.legochembio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service